Bioxcel therapeutics receives fda breakthrough therapy designation for bxcl501 for the acute treatment of agitation associated with dementia

Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options for dementia related agitation designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options for dementia related agitation
BTAI Ratings Summary
BTAI Quant Ranking